Expert Opinion
Explore independently-led content from leading experts on the use of αTNF biosimilars to treat three conditions and discover:
- The role of αTNF biosimilars in rheumatoid arthritis and the common misconceptions of biosimilars in rheumatology
- The considerable burden of hidradenitis suppurativa and the future of biosimilars in dermatology
- Strategies for treating inflammatory bowel disease with αTNF biosimilars
Do you know the latest insights on the use of αTNF biosimilars in rheumatoid arthritis, hidradenitis suppurativa, and inflammatory bowel disease? In these illuminating expert-led interviews, Professor Thomas Dörner, Dr Joana Cabete, and Dr Nick Kennedy explore αTNF treatment initiation, optimisation, and maintenance, as well as αTNF treatment during COVID-19.
Also find out about the future of biosimilars in dermatology and the most common misconceptions of biosimilars in rheumatology with Professor Tiago Torres and Professor Joao Goncalves.
In this Section
Know the latest insights on the use of αTNF biosimilars in rheumatoid arthritis? Watch these videos on treatment initation and optimisation.
Biological disease-modifying antirheumatic drugs (DMARDs), such as anti tumour necrosis factor (αTNF), are an important component of treatment for patients with rheumatic diseases1.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Want to hear the latest on hidradenitis suppurativa? Watch the videos below to learn about the unmet needs of this disease, the use of αTNF treatment and the impact of COVID-19.
Hidradenitis suppurativa (HS) is a prevalent and devastating inflammatory skin disease characterised by painful recurrent abscesses, foul-smelling purulent drainage, sinus tract and fistula formation, and disfiguring scarring involving intertriginous body sites1.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Watch these videos to find out the latest advice on treating inflammatory bowel disease covering the initiation, optimisation and maintenance of treatment and impact of COVID-19.
Inflammatory bowel diseases can result in debilitating physical and psychosocial symptoms for patients and affect society through loss of schooling, absenteeism, and health-care costs1.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.